ESR1 and breast cancer: In line with these results, the serum level of COMP has also been shown to be an independent predictive factor of breast cancer patients’ survival comparable with classical prognostic markers, such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) [6].